Format

Send to

Choose Destination
J Endocrinol Invest. 2017 Jan;40(1):83-89. doi: 10.1007/s40618-016-0535-4. Epub 2016 Aug 29.

Influence of short-term selenium supplementation on the natural course of Hashimoto's thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial.

Author information

1
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Piazza Miraglia n 2, 80100, Naples, Italy.
2
Unit of Internal Medicine and Endocrinology, Fondazione Salvatore Maugeri IRCCS, University of Pavia, Pavia, Italy.
3
Department of Pediatric Radiology, University Hospital Federico II, Naples, Italy.
4
Division of General and Oncologic Surgery, Department of Anesthesiology, Surgical and Emergency Sciences, Second University of Naples, Naples, Italy.
5
Endocrine and Metabolic Unit, Department of Medical and Surgical Sciences, Clinica Medica, 2nd Medicina, University of Brescia, Spedali Civili di Brescia, Brescia, Italy.
6
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Piazza Miraglia n 2, 80100, Naples, Italy. daniela.pasquali@unina2.it.

Abstract

BACKGROUND:

The real efficacy of selenium supplementation in Hashimoto's thyroiditis (HT) is still an unresolved issue.

OBJECTIVES:

We studied the short-term effect of L-selenomethionine on the thyroid function in euthyroid patients with HT. Our primary outcome measures were TSH, thyroid hormones, thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TGAb) levels and thyroid echogenicity after 6 months of L-selenomethionine treatment. The secondary outcome measure was serum CXCL10 levels.

METHODS:

In a placebo-controlled randomized prospective study, we have enrolled untreated euthyroid patients with HT. Seventy-six patients were randomly assigned to receive L-selenomethionine 166 µg/die (SE n = 38) or placebo (controls n = 38) for 6 months. TSH, free T4 (FT4), free T3 (FT3), TPOAb and CXCL10 serum levels were assayed at time 0, after 3 and 6 months. An ultrasound examination of the left and right thyroid lobe in transverse and longitudinal sections was performed. A rectangular region, the region of interest, was selected for analysis.

RESULTS:

TSH, FT4, FT3, TPOAb, thyroid echogenicity and CXCL10 were not statistically different between SE and control groups at time 0, after 3 and 6 months. In the SE group, FT4 levels were significantly decreased (P < 0.03) after 3 months, while FT3 increased (P < 0.04) after 3 and 6 months versus baseline values. In the control group, the FT3 decreased after 3 and 6 months (P < 0.02) compared to baseline.

CONCLUSION:

The short-term L-selenomethionine supplementation has a limited impact on the natural course in euthyroid HT. Our results tip the balance toward the ineffectiveness of short-term L-selenomethionine supplementation in HT.

KEYWORDS:

1-selenomethionine; CXCL 10 levels; Hashimoto's thyroiditis; Thyroid echogenicity; Thyroid function

PMID:
27572248
DOI:
10.1007/s40618-016-0535-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center